Cardiovascular disease and cancer are the two leading causes of morbidity and mortality in
the world. The emerging field of cardio-oncology has revealed that these seemingly …

Metabolic syndrome (MetS) is a well established risk factor for cardiovascular (CV) diseases.
In addition, several studies indicate that MetS correlates with the increased risk of cancer in …

Background Studies assessing whether heart failure (HF) is associated with cancer and
cancer-related mortality have yielded conflicting results. Objectives This study assessed …

Aims The prognosis and quality of life of heart failure patients is determined to a significant
extent by co‐morbidities. New data suggest that heart failure may be associated with an …

Background Following the availability of new drugs for chronic heart failure (HF) with
reduced ejection fraction (HFrEF), we sought to provide an updated and comparative …

Aims Cancer and heart failure (HF) share risk factors, pathophysiological mechanisms, and
possibly genetics. Improved HF survival may increase the risk of cancer due to a competing …

In the last 5 years, growing attention has been paid to the occurrence of cancer in
individuals who already have heart failure (HF). 1 The issue of cancer in HF was further …

Aims Heart failure (HF) therapy trials usually exclude cancer patients. We examined the
association between cancer history and outcomes in trial participants with HF and reduced …

Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-
associated mortality, compared to subjects free of HF. While both the prevention and …

The current global prevalence of heart failure is estimated at 64.34 million cases, and it is
expected to increase in the coming years, especially in countries with a medium-low …